GR 3027

Drug Profile

GR 3027

Alternative Names: GR-3027

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Umecrine Cognition
  • Class Hepatoprotectants; Neuroprotectants; Small molecules
  • Mechanism of Action GABA-A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypersomnia
  • Phase I/II Hepatic encephalopathy

Most Recent Events

  • 24 Aug 2017 Phase-II clinical trials in Hypersomnia in Finland (PO) (EudraCT2017-002127-16)
  • 19 Apr 2017 Interim pharmacokinetics and adverse events data from a phase-I trial in Hepatic encephalopathy presented at the International Liver Congress (ILC-2017)
  • 17 Mar 2017 Phase-I/II clinical trials in Hepatic encephalopathy in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top